Solventum’s Earnings Call: Shareholder Return vs. M&A Focus, 2027 Growth Signals Clash

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $2.2B, up 9.5% organically YOY
• EPS: $2.55 per share; excluding advanced orders and tariff refunds, $1.73 per share
• Gross Margin: 60.1%, up 410 basis points YOY; excluding $100M tariff refund, 55.6%, down 40 basis points YOY
• Operating Margin: 28.4%; excluding 670 basis point benefit from advanced orders and tariff refund, 21.7%, down 20 basis points YOY

Guidance:

• Organic sales growth tightened to 2.5% to 3% (3.5% to 4% excluding skew exits), up from 2% to 3%.
• Operating margin guidance increased to 22.2% to 22.7%, up from 21% to 21.5%.
• EPS guidance raised to $7.10 to $7.20, up from $6.40 to $6.60.
• Free cash flow expected to be $200M to $300M, up from approximately $200M.

Business Commentary:

Revenue Growth and Advanced Orders:

• Solventum reported sales of $2.2 billion for Q2 2026, representing an organic growth of 9.5% and reported growth of 2.2%.
• Advanced orders contributed approximately $125 million to sales in the quarter, with a significant portion of this expected to reverse in Q3.
• The growth was driven by strong execution across segments and planned advanced orders to mitigate ERP cutover disruptions.

MedSurg and Dental Segment Performance:

• The MedSurg segment delivered $1.4 billion in sales, with an organic growth of 8.9%, while the Dental segment reported $396 million in sales, indicating an organic growth of 15.2%.
• Growth in MedSurg was driven by advanced orders and adoption of antimicrobial solutions, and Dental benefited from innovative new product launches.
• The performance reflects strong demand in durable markets and effective commercial execution.

Operating Margin and Financial Outlook:

• Solventum's gross margin was reported at 60.1%, including a one-time tariff refund benefit of $100 million. Excluding this, the margin was 55.6%, impacted by tariffs and inflation.
• The company raised its operating margin outlook to a range of 22.2% to 22.7%, reflecting the full benefit of tariff refunds.
• The improved outlook is supported by strong operational performance and effective cost management.

Portfolio Optimization and Separation Strategy:

• The company announced plans to separate its Health Information Systems (HIS) business, aiming to unlock shareholder value and focus on core med-tech operations.
• The separation is expected to enhance strategic fit and value, allowing HIS to capitalize on AI advances independently or with a scale player.
• This move aligns with the company's balanced capital allocation strategy and is expected to improve overall portfolio focus.

Share Repurchase and Capital Allocation:

• Solventum repurchased nearly 4 million shares for $288 million under its authorized share repurchase program during the quarter.
• The company continues to prioritize a balanced capital allocation strategy, including tuck-in acquisitions and share repurchases, supported by a strong balance sheet.
• The repurchase program is part of a broader plan to drive shareholder value and manage capital efficiently.

Sentiment Analysis:

Overall Tone: Positive

• Management stated the quarter 'came in ahead of plan, top and bottom line,' 'delivered across the board,' and is 'clearly on track to achieving our long-range plan earlier than expected.' They also noted 'strong execution,' 'healthy performance across every segment,' and 'confidence in our full-year objectives.'

Q&A:

• Question from Jason Bednar (Piper Sandler): Had you received any outside interest in the asset that helps spur this decision? Maybe talk about how far long you are just in this process and in the kind of the separation decision. And then, you know, I'm interested just in the release, you're framing the decision as transitioning to a stronger growth profile, but maybe elaborate on that since HIS has been growing above the corporate average over the last several years.
  Response: Management believes separating the HIS business will unlock greater shareholder value by allowing it to focus on its core med-tech businesses (MedSurg and Dental) and enable HIS to maximize innovation and investment as a standalone or combined entity, as it sees significant growth opportunities in areas like autonomous coding.

• Question from Jason Bednar (Piper Sandler): Are you agnostic as far as the transaction form, assuming when one occurs, how that takes place, and maybe walk through some of the considerations that you have with respect to speed of transaction and the value considerations when we think about like tax leakage or you know just overall value on a spin versus a sale and maybe the final thing of just remind us how integrated um his is into solventum.
  Response: The company is agnostic on the separation method (spin or sale) and will use proceeds and separation method to maximize shareholder value. The HIS business is not highly integrated with Solventum, making separation easier, and there is existing inbound interest.

• Question from Brian Zimmerman (U.S. Bancorp): You know, when you back out the advance orders, we saw a nice acceleration in the underlying businesses in Med-Surg and Brian, I wonder if you could kind of speak to the health of the market, what you're seeing, you know, again, X the advanced orders.
  Response: Management is not currently seeing any softness in procedures or business momentum across MedSurg, Dental, and HIS segments, despite external noise about potential market utilization changes.

• Question from Brian Zimmerman (U.S. Bancorp): The other question, I mean, the cash flow is picking up. You're obviously got a share buyback going on. you know, let's say the business gets done in some fashion, you're going to have, you know, certainly more cash proceeds or cash on the balance sheet. And Wade, I'm curious kind of how you think about putting that to work.
  Response: Proceeds from the HIS separation would be used to pay down debt to maintain solid investment-grade ratings, with the majority applied to shareholder return applications like buybacks, consistent with the company's balanced capital allocation strategy, while maintaining a tuck-in acquisition focus.

• Question from Travis Deed (Bank of America): I guess first, you know, the healthcare IT business is a pretty high margin business. And so how are you thinking about managing the EPS solution if that is sold? Is there a willingness to buy back stocks so you can kind of protect earnings there? And then I don't know if you'd comment on why announce the intent separate versus just announcing when something's done.
  Response: Management is evaluating separation methods and use of proceeds to minimize EPS dilution and maximize shareholder value. The decision to announce now was driven by the decision being made, the need to control external noise, and the fact that the businesses (MedSurg and Dental) have synergies in IP and R&D capabilities.

• Question from Stephen Valliquette (Misoo Securities): Just to follow up on the question earlier on the overall market utilization trends, from our view, it seemed like there was maybe not a major change in patient volumes overall, but maybe just an acceleration in the shift of patients from inpatient to outpatient setting. So I guess in light of that, I'm curious if you would maybe endorse that same sort of view or maybe saw something different.
  Response: Management has not seen an acceleration in the shift from inpatient to outpatient settings recently; this movement has been occurring for a while. The company's broad product usage across hospitals and ASCs makes this trend less impactful on its business.

• Question from Brett Fishman (KeyBank Capital Markets): Obviously a lot of noise here but one uh metric that stood out was just a very high level of growth from acera um maybe just expand a little bit on what drove the performance this quarter and thoughts on durability.
  Response: Acera's strong performance is driven by its differentiated synthetic tissue matrix technology in an attractive market, leveraging existing customer relationships, and it is expected to continue as a double-digit grower, becoming a larger part of the portfolio over time.

• Question from Brett Fishman (KeyBank Capital Markets): And then I'll just ask one more follow-up on the revenue trend. You're just giving the noise, the ERP, yeah, like the buy-in ahead of the ERP. You know, guidance came up by 50 dips on an underlying basis. So maybe just removing some of the moving pieces around timing, what got better versus the last time you guided that's driving the increase?
  Response: Confidence in the full-year guide was raised due to strong first-half normalized performance at the high end of previous guidance. The second half will see a sequential deceleration due to the reversal of advanced orders in Q3, but Q4 is expected to return to positive growth, resulting in flat second-half growth.

• Question from Rick Weiss (Stifel): Maybe start off with a little more – help us understand a little more about the advanced borders. I get the concept, $125 million, just in case there's disruption. But just as I reflect on it, I was just wondering, is this a quarter's worth of orders? Is it all used up by the end of this year and so it won't have any impact on next year?
  Response: The $125M in advanced orders is not a full quarter's worth and will be used up in Q3. It will create a headwind to revenue and EPS in Q3, with a mirror-image benefit in Q2, and the company expects earnings per share to accelerate from the first half to the second half when normalized.

• Question from Rick Weiss (Stifel): And just as a follow up question, Brian and Wade both, you talked about it from various perspectives, the sort of the end of this long very difficult to achieve, but faster than expected process through implementing these ERP cutovers and transitions. And Brian, you repeatedly talked about the language like it will free up people, there'll be cost savings, et cetera, et cetera. I assume it lowers costs. maybe help us think, once it's all done, from your perspective, what are you going to be able to do?
  Response: Post-ERP cutover, management plans to redeploy sharp minds from problem-solving during the cutover to focus on growth drivers, savings programs, and innovation, which are currently being distracted from, to accelerate growth and margin expansion.

• Question from Nathan Trey (Wells Fargo): Brian, I appreciate your earlier comments on 2027, but any finer point you can give on what parts of the portfolio would drive the acceleration relative to 26? And then when you say acceleration, would that be relative to the 3.5 to 4 that you're guiding when adjusting for the skew exits?
  Response: Acceleration in 2027 is expected relative to the 3.5% to 4% normalized growth guide (excluding skew exits), driven by all businesses (MedSurg, Dental, HIS) focusing on growth drivers, innovation launches, and specialized sales.

• Question from Nathan Trey (Wells Fargo): Okay thanks for that and so heading into 27 i guess how should we think about the p l and i guess the level of noise from stranded costs or any remaining the synergies is that all cleared away as we head into 27.
  Response: Most separation-related costs and synergies will be washed out in 2027, but the company will provide future updates on the financial impact of the HIS separation, similar to the process with the purification and filtration divestiture.

• Question from Vic Chopra (BMO): With this HIS separation, you know, does this transaction mark the final major portfolio action under the transformation plan, or are there other businesses that could be candidates for divestiture or strategic review?
  Response: While the company is focused on being a dedicated med-tech company post-separation, portfolio optimization is an ongoing process, and the company will continue to evaluate potential actions at segment, business, or product levels in the future.

• Question from Vic Chopra (BMO): Okay thank you and then a quick follow-up you know you talked about 20 product launches by early 2028 including some significant advanced wound care launches next year i'm just curious which launches have the greatest potential to move the wanger or is this more of a portfolio effect story
  Response: The company will provide more details on the product launches at the upcoming Investor Day in Q1 2027. The growth is seen as a portfolio effect driven by the underpenetration of advanced, differentiated solutions across the five growth drivers, not just individual products.

Contradiction Point 1

Capital Allocation Strategy Post-HIS Separation

It involves a change in the company's stated priority for using separation proceeds, which impacts strategic direction and investor expectations regarding capital use.

What were the key factors driving U.S. Bancorp's performance during Brian Zimmerman's earnings call? - Brian Zimmerman (U.S. Bancorp)

2026Q2: If there are significant proceeds... the capital allocation strategy will be more biased towards shareholder return applications (like share repurchases). A portion of proceeds will be used to buy down debt... - Brian Hanson(CEO)

How will the separation of HIS and its potential proceeds influence your approach to capital allocation, including debt paydown, M&A, and shareholder returns? - Brian Zimmerman (U.S. Bancorp)

2026Q2: The capital allocation strategy remains balanced. The company will continue its tuck-in acquisition strategy... The focus is on disciplined, value-driven capital deployment. - Wade McMillan(CFO)

Contradiction Point 2

Future Growth Outlook and 2027 Acceleration

It involves conflicting signals on the expected growth rate for 2027, which is a key financial forecast impacting investor expectations.

Nathan Trey (Wells Fargo) - Nathan Trey (Wells Fargo)

2026Q2: The 2027 acceleration is expected to be better than the 3.5-4% X-skew number... - Brian Hanson(CEO)

What parts of the portfolio will drive the 2027 acceleration relative to the 3.5-4% guide, and how should we think about the P&L heading into 2027 regarding stranded costs or remaining synergies? - Nathan Trey (Wells Fargo)

2026Q2: Acceleration in 2027 is expected across all businesses... with a focus on innovation, product launches, and sales specialization. - Bryan Hanson(CEO)

Contradiction Point 3

Nature and Impact of Advanced Orders

It involves contradictory statements on whether advanced orders represent a full quarter's benefit and their impact on the P&L, affecting financial modeling and near-term performance expectations.

Rick Weiss (Stifel) - Rick Weiss (Stifel)

2026Q2: The $125M in advanced orders is not a full quarter's worth and will be used up in Q3. The company will then need to rebuild inventory to normal levels... The advanced orders are a mitigation strategy for ERP-related challenges. - Brian Hanson(CEO)

Can you provide an update on the $125M advanced orders, including their timeline for use and impact on second-half P&L, as well as the ERP cutover costs and how the savings will be utilized? - Brett Fishbin (KeyBanc Capital Markets)

2026Q1: An estimated over $100 million in additional sales in Q2 is expected due to advanced ordering ahead of the Q3 ERP cutover... All advanced orders in Q2 are expected to be offset in the second half of 2026, mostly in Q3. - Brett Fishbin(CFO)

Contradiction Point 4

Strategy and Timing for Portfolio Optimization

It involves a contradiction on whether portfolio optimization is an ongoing, flexible process or a decision largely concluded post-3M separation, impacting strategic flexibility and investor perception of future moves.

Vic Chopra (BMO) - Vic Chopra (BMO)

2026Q2: The company continually evaluates portfolio optimization at various levels (segment, business, product). However, the post-separation company is now viewed as a true med-tech company with the MedSurg and Dental businesses. - Brian Hanson(CEO)

"Does the HIS separation mark the completion of major portfolio actions under the transformation plan, or are further divestitures anticipated, and which upcoming product launch, including advanced wound care, has the highest potential to significantly impact results?" - Travis Steed (Bank of America)

2026Q1: As the separation from 3M moves further in the rearview, flexibility increases. They are looking for transactions that unlock shareholder value, whether exits or additions (like Acera). - Bryan Hanson(CEO)

Contradiction Point 5

Growth Outlook and EPS Guidance

It involves conflicting signals on near-term growth drivers and EPS trajectory, affecting the understanding of the company's financial performance and future prospects.

Nathan Trey (Wells Fargo) - Nathan Trey (Wells Fargo)

2026Q2: The 2027 acceleration is expected to be better than the 3.5-4% X-skew number and is anticipated from all three businesses (MedSurg, Dental, HIS). The acceleration will be driven by focus on the five growth drivers... Normalizing for these, EPS is expected to accelerate in the second half. - Brian Hanson(CEO)

What factors are expected to drive the 2027 acceleration relative to the 3.5-4% guide, and how should we assess the P&L implications regarding stranded costs and remaining synergies? - Jason Bednar (Piper Sandler)

20260227-2025 Q4: Organic sales growth is expected to be just under 1% for the quarter [Q1 2026]. The rest of the year is more stable, though there will be a first-half/second-half volume dynamic... The high end of the 2-3% guide (3-4% ex-SKU) is already aligned with the low end of the long-range 4-5% target... - Wayde McMillan(CFO)